Navigation Links
Gerresheimer Sets up New Production Facility for Insulin Pen Systems in Brazil
Date:1/11/2010

    DUSSELDORF, Germany, January 11 /PRNewswire-FirstCall/ --
    - Expansion of Cooperation With Diabetes Leader Novo Nordisk
    - Important Step in the Worldwide Development of Medical Plastic Systems

The Gerresheimer Group has set up a new facility for medical plastic systems in Indaiatuba (Brazil). The plant is to commence operations early in 2010. On the basis of a long-term cooperation agreement with Novo Nordisk, components will be produced with state-of-the-art technology for insulin pen systems for diabetics.

Insulin pens are drug-delivery devices in ball-point pen format which allow diabetes patients to inject themselves with the regularly required insulin dose safely and almost painlessly. Novo Nordisk as the world's leading insulin producer has contracted Gerresheimer to manufacture components for its insulin pens. Novo Nordisk has a large insulin plant in Brazil which will in future be supplied locally by the new technology center of the Gerresheimer Group. For Gerresheimer this is already the fourth production plant in South America in addition to two existing plants for standardized pharma plastic packaging in Brazil and one in Argentina.

Apart from the new production facility in Brazil, Gerresheimer already has two other production facilities for pen systems in Europe.

"Cooperation with Novo Nordisk in Brazil is of substantial strategic importance for us. We support the customer in developing new markets and at the same time expand our technological base in South America," says Gerresheimer CEO Dr. Axel Herberg.

About Gerresheimer

Gerresheimer employs around 10,000 people in 40 locations in Europe, America and Asia. In the financial year 2008, worldwide sales totaled EUR1.06bn. The product portfolio ranges from pharma-ceu-tical vials made of glass and plastic through to complex drug-delivery systems for the pharma & healthcare industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterized by high technical and regulatory barriers.

    Contact Press

    Burkhard Lingenberg
    Director Corporate Communication & Marketing
    Phone +49-211-6181-250
    Fax +49-211-6181-241
    e-mail b.lingenberg@gerresheimer.com

    Contact Investor Relations

    Anke Linnartz
    Director Corporate Investor Relations
    Phone +49-211-6181-314
    Fax +49-211-6181-121
    e-mail a.linnartz@gerresheimer.com


SOURCE Gerresheimer AG


'/>"/>
SOURCE Gerresheimer AG
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Gerresheimer Holds its own in Difficult Environment
2. Gerresheimer Sells Technical Plastics Business
3. Gerresheimer Opens New High-Tech Production Facility for Pharma Glass in China
4. 2008 a Record Year for Gerresheimer
5. Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009
6. Gerresheimer Substantially Increases Quarterly Operating Profit
7. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
8. Gerresheimer Further Increases its Sales and Earnings Power
9. Gerresheimer Discontinues Marginal Operations
10. Moodys Raises Rating for Gerresheimer
11. Gerresheimer: Record Year in 2007 and Positive Outlook for 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):